G1359A polymorphism of the cannabinoid receptor gene (CNR1) on anthropometric parameters and cardiovascular risk factors in patients with morbid obesity;G1359A polimorfismo del receptor CB1 endocanabinoide (CNR1) en parámetros antropométricos y riesgo cardiovascular en pacientes con obesidad mórbida

Nutricion Hospitalaria

Volumn 24, Issue 6, 2009, Pages 688-692

  De Luis, D A ^a   Gonzalez Sagrado M ^a   Aller, R ^a   Izaola, O ^a   Conde, R ^a   Perez Castrillon J L ^a   Romero, E ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Adipocytokines; Cannabinoid receptor; Cardiovascular risk factors; Obesity; Polimorphism

Indexed keywords

ADIPOKINES; ADULT; ALLELES; ANTHROPOMETRY; BLOOD PRESSURE; C-REACTIVE PROTEIN; CALORIMETRY, INDIRECT; CARDIOVASCULAR DISEASES; CYTOKINES; DIET RECORDS; ELECTRIC IMPEDANCE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; OBESITY, MORBID; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; RISK FACTORS;

EID: 73249130146     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2009.24.6.4453     Document Type: Article

References (24)

1. Matsuzawa Y. Adipocytokines: Emerging therapeutic targets. Current Atherosclerosis Reports 2005; 7: 58-62.
2. Ameri A. The effects of cannabinnoids on the brain. Prog Neurobiol 1999; 58: 315-348.
3. Brown SM, Warger- Miller J, Mackie K. Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim Biophys Acta 2002; 1576: 255-264.
4. Fride E. Endocannabinoids in the central nervous system an overview. Prostaglandins Leukot Essent Fatty acids 2002; 66: 221-233.
5. Felder CC, Glass M. Cannabinoid receptors and theirendogenous agonists. Ann Rev Pharmacol Toxicol 1998: 38: 179-200.
6. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P,. CB1 cannabinoid receptor knockout in mice leads to leannes, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640-648.
7. Gadzicki D, Muller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes 1999; 13: 321-323.
8. Duart MJ, Arroyo CO, Moreno JL. Validation of a insulin model for the reactions in RIA. Clin Chem Lab Med 2002; 40: 1161-1167.
9. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher Df. Homesotasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-414.
10. Feurer ID, Mullen JL. Bedside measurement of resting energy expenditure and respiratory quotient via indirect calorimetry. Nutr Clin Pract 1986; 1: 43-49.
11. Pichard C, Slosman D, Hirschel B, Kyle U. Bioimpedance analysis: an improved method for nutritional follow up. Clin Res 1993; 41: 53.
12. Mataix J, Mañas M. Tablas de composición de alimentos españoles. Ed: University of Granada, 2003.
13. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. Leptin. Regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
14. Engeli S, Jana B, Mareike F, Kerstin G, Jürgen J, Sandor B. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843.
15. Gazzerro P, Caruso MG, Notarnicola M, Misciagna G, Guerra V, Laezza C, Bifulco M. Association between cannabinoid type 1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes 2007; 31: 908-912.
16. Jaeger J, Mattevi V, Callegari-Jacques SD, Hutz MH. Cannabinoid type 1 receptor gene polymorphisms are associated with central obesity in a Southern Brazilian population. Disease Markers 2008; 25: 67-74.
17. Aberle J, Flitsch J, Alessia N, Mann O, Busch P, Peitsmeier P, Ulrich F. Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes. Molecular Genetics and Metabolism 2008; 95: 188-191.
18. Russo P, Strazzullo P, Cappuccio F, Tregouet D, Lauria F, Loguercio M, Barba G y cols. Genetic variations at the endocannabinoid type 1 receptor gene (CRN1) are associated with obesity phenotypes in Men. J Clin Endo and Metan 2007; 92: 2382-2389.
19. Peeters A, Beckers S, Mertens I, Van Hul W, Van Gaal L. The G1422A variant of the endocannabinoid receptor gene is associated with abdominal adiposity in obese men. Endocr 2007; 31: 138-141.
20. Benzinou M, Chevre JC, Ward K, Lecoeur C, Dina C, Lobbens S, y cols. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index European population. Human Molecular Genetics 2008; 17: 1916-1921.
21. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A. The CB1 receptor antagonist rimonabant reverses the diet induced obesity phenotype through the regulation of lipólisis and energy balance. FASEB J 2005; 19: 1567-1569.
22. Bensaid M, Gary Bobo M, Esclangron A, Maffrand JP, Le Fut G, Oury DOnat F. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp 30 mRNA expresión in adipose tissue of obese fa/fa rats and in cultures adipocyte cells. Mol Pharmacol 2003; 63: 908-914.
23. Poirier B, Bidoauard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes, Obes, Metab 2005; 7: 65-72.
24. Baye TM, Zhang Y, Smith E, Hillard CJ, Gunnell J, Myklebust J, James R, Kissebah AH y cols. Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. Pharmacogenomics 2008; 9:1647-1656.